James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Valeant Pharmaceuticals Intl Inc: It’s Time to Take a Shot on VRX

Valeant Pharmaceuticals (VRX) has been the market's favorite target for a while, but it's ceased to become fun beating up on the company. Now look for the sentiment tide to turn, along with the stock.

SunEdison Inc: How to Trade SUNE Stock From Here

SunEdison (SUNE) has been run through the wringer, but it's still trading. The question is, what's left, and what do you do about it (if anything)?

Facebook Inc (FB) Stock Owners Needn’t Worry About Oculus Rift Critiques

Facebook (FB) stock hasn't been helped by a less-than-perfect debut of the Oculus Rift headset, but the critiques can't be surprising, and aren't unusual.

Why Allergan plc Ordinary Shares (AGN), Baker Hughes Incorporated (BHI) and GoDaddy Inc (GDDY) Are 3 of Today’s Worst Stocks

Tuesday was particularly tough on owners of Allergan plc (AGN), Baker Hughes (BHI) and Godaddy (GDDY). Here's the deal.

Allergan, Pfizer Inc. Fall Prey to Tax-Inversion Hawks (AGN, PFE)

Pfizer (PFE) and Allergan (AGN) could still team up if they wanted to, but with new Treasury rules in place, why would they want to?